Previous efforts to differentiate human embryonic stem cells (hESCs) into endothelial cells have not achieved sustained expansion and stability of vascular cells. To define vasculogenic developmental pathways and enhance differentiation, we used an endothelial cell-specific VE-cadherin promoter driving green fluorescent protein (GFP) (hVPr-GFP) to screen for factors that promote vascular commitment. In phase 1 of our method, inhibition of transforming growth factor (TGF)b at day 7 of differentiation increases hVPr-GFP + cells by tenfold. In phase 2, TGFb inhibition maintains the proliferation and vascular identity of purified endothelial cells, resulting in a net 36-fold expansion of endothelial cells in homogenous monolayers, which exhibited a transcriptional profile of Id1 high VEGFR2 high VE-cadherin + ephrinB2 + . Using an Id1-YFP hESC reporter line, we showed that TGFb inhibition sustains Id1 expression in hESC-derived endothelial cells and that Id1 is required for increased proliferation and preservation of endothelial cell commitment. Our approach provides a serum-free method for differentiation and long-term maintenance of hESC-derived endothelial cells at a scale relevant to clinical application.
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Human embryonic stem cells (hESCs), which self-renew indefinitely 1 , offer a plentiful source of endothelial cells for therapeutic revascularization. However, few studies have identified specific developmental stimuli sufficient to support the specification and maintenance of large numbers of functional and vascular-committed endothelial cells from hESCs [2] [3] [4] [5] [6] [7] . Although small numbers of hESC-derived endothelial cells have been generated in short-term cultures, these cells have not been subjected to sustained expansion, angiogenic profiling or interrogated as to the stability of vascular fate. As a result, molecular pathways that maintain vascular identity and long-term expansion of hESC-derived endothelial cells remain unknown.
To detect the emergence of endothelial cells from differentiating hESCs in real time, we generated a cell line for endothelial cell-specific lineage tracing. We cloned a 1.5-kilobase fragment from a bacterial artificial chromosome (BAC) containing the genomic locus of the human endothelial cell-specific gene VE-cadherin (CDH5). The promoter sequence of this gene, encompassing a region upstream of exon 1, was inserted into a lentiviral vector upstream of GFP (hVPr-GFP; Fig. 1a) . Human endothelial cells transduced with this vector showed robust expression of GFP, in contrast to transduced human mesenchymal and fibroblastic cells, which did not express GFP (Supplementary Fig. 1a-c) . Endothelial-specific expression of the reporter was also evident in transduced, spontaneously differentiating hESCs (RUES1 line; Fig. 1b and Supplementary Fig. 1d-j) : hVPr-GFP + cells were organized into capillary-like structures expressing endothelial cell markers, including VE-cadherin, CD31 and CD34 ( Supplementary  Figs. 1d-g and 2a,b) , and were negative for alpha smooth muscle actin (α-SMA) and CD45, a marker of hematopoietic cells ( Supplementary  Figs. 1h-j and 2c) .
Using the hVPr-GFP hESC reporter line, we tracked the chronology and geometry of vasculogenic differentiation in differentiating embyroid bodies by time-lapse confocal microscopy. Beginning at day 5, we observed the specification and emergence of hVPr-GFP + cells (Supplementary Video 1 and Supplementary Fig. 3) , and by day 8, hVPr-GFP + cells co-expressing vascular endothelial growth factor receptor (VEGFR)2 and CD31 (Fig. 1c) formed motile vessel-like structures (Supplementary Video 2) . These data validated the ability of the hVPr-GFP reporter construct to specifically identify and track hESC-derived nascent endothelial cells.
We used the reporter line to develop a chemically defined, serum-free method for enhancing vascular differentiation. In phase 1, heterogenous embryoid body cultures of hVPr-GFP hESCs were sequentially stimulated with bone morphogenetic protein (BMP)4, activinA, fibroblast growth factor (FGF)-2 and VEGF-A [8] [9] [10] (Fig. 1d) . Although these growth conditions promoted formation of hVPr-GFP + structures ( Supplementary Fig. 4 and Supplementary Videos 3 and 4) , the yield of dissociated hVPr-GFP + endothelial cells obtained by fluorescence-activated cell sorting (FACS) was low, and these few isolated endothelial cells could not be expanded without the majority of cells assuming a non-endothelial cell phenotype of hVPr-GFP + CD31 + cells beginning at about day 9, while reducing expression of α-SMA (Fig. 2b,c) . After isolation from heterogenous cultures by FACS, endothelial cells grown in the absence of TGFb inhibition retained high expression of CD31 but also expressed α-SMA (Supplementary Video 5), indicating that these endothelial cell-like cells had not assumed a terminally committed vascular fate.
Expression of α-SMA in hESC-derived endothelial cells suggested a degree of plasticity that is not present in terminally differentiated endothelial cells (human umbilical vein endothelial cells; HUVEC, Fig. 2b) . Indeed, extended culture (>10 d after FACS isolation) of hESCderived endothelial cells in the absence of TGFb inhibition yielded a substantial number of cells co-expressing VE-cadherin and α-SMA (Fig. 2d) . One explanation for the increased percentage of endothelial cells in SB431542-stimulated cultures is maintenance of the vascularcommitted state after specification. To test the capacity of TGFb inhibition to promote expansion of pure populations of hESC-derived endothelial cells, we dissociated day 14 differentiation cultures, isolated (data not shown). We therefore screened for bioactive small molecules that would improve vascular differentiation. Screening of >20 molecules associated with early developmental signaling pathways ( Supplementary  Table 1) showed that the TGFb-inhibitory molecule SB431542 (ref. 11) reproducibly increased the yield of hVPr-GFP + cells. Adding SB431542 to differentiation cultures at day 7 resulted in the formation of hVPr-GFP + VE-cadherin + monolayers (Fig. 1e,f) , which, upon dissociation, yielded tenfold more hVPr-GFP + endothelial cells than cultures stimulated by cytokines alone (Fig. 1g-i) . No hVPr-GFP + cells were generated if SB431542 was added at the onset of differentiation (day 0), suggesting that vascular commitment depends on active TGFb/activin/nodal signaling before day 7.
Kinetic analysis of differentiation suggested a shift from a pluripotent phenotype (Oct3/4 + ; 
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In aggregate, TGFb inhibition in phase 1 and 2 resulted in a 36-fold expansion in the total number of vascular-committed hESC-derived endothelial cells, with 7.4 CD31 + VE-cadherin + endothelial cells generated from every one hESC input over 20 d, compared with 0.2 endothelial cells per input hESC derived from control culture conditions (Fig. 2j) . Similar levels of expansion of hESC-derived endothelial cells were achieved with four additional hESC lines and one induced pluripotent stem cell line using the same protocol except that either SB431542 or soluble TGFbRII hVPr-GFP + cells by FACS and expanded them for an additional 5 d with or without SB431542 (Phase 2, Fig. 2e-i) . SB431542-treated cultures yielded more cells in the 5-d period, and a higher percentage of the population retained an α-SMA − CD31 + VE-cadherin + phenotype (Fig.  2e-h ). In addition to preserving the vascular phenotype, SB431542 also increased cell proliferation, as indicated by a higher percentage of phospho-histoneH3 + (PHH3) mitotic endothelial cells ( 19 , we focused on Id1 as a potential mediator of the pro-angiogenic effect of TGFb-inhibition observed in our study. To track Id1 expression in live hESC differentiation cultures, we used receptor decoys was used interchangeably to inhibit activation of the activin/nodal branch of TGFb superfamily signaling ( Supplementary  Fig. 5a-e) . These results demonstrate that the effect of TGFb inhibition shown for the RUES1 line is applicable to other pluripotent cell lines.
To define the vasculogenic transcriptional signature of hESC-derived endothelial cells at different time points during phases 1 and 2, we carried out Affymetrix microarray analyses of several hESC-derived populations and mature cell types (Fig. 3a) . The yield of freshly isolated phase 1 endothelial cells in the absence of TGFb inhibition was insufficient for microarray analyses, underscoring the value of our approach for generating sufficient expanding (phase 1) and vascular-committed (phase 2) endothelial cells for molecular profiling.
Phase 1 hESC-derived endothelial cells showed increased levels of factors typical of arterial-like endothelial cells (VEGFR2, VEGFR1, Id1, CD31, CD34, VE-cadherin, vWF, thrombomodulin, ephrinB2 and E-selectin) but 
To demonstrate that our cultured endothelial cells could form functional vessels, we grew purified hVPr-GFP + cells from day 14 differentiation cultures for an additional 8 d in the presence of SB431542. These endothelial cells showed high proliferative potential (up to ten cell divisions) and generated homogenous hVPr-GFP + VE-cadherin + monolayers (Fig. 4e-g ) with retention of hVPr-GFP fluorescence at the single-cell level (arrowheads in Fig. 4g ). These cells were subcutaneously injected in Matrigel plugs into nonobese (NOD)/severe combined immunodeficient (SCID) mice and 10 d later extracted after intravenous injection of lectin into live animals. In Matrigel plugs, hVPr-GFP + cells co-localized with lectin + cells, forming chimeric vessels along with host cells (Fig. 4h-i and Supplementary Videos 8 and 9 ). These data indicated that the endothelial cells generated by our methods could function in vivo.
A prerequisite to therapeutic vascularization using hESC-derived cells is generation of abundant durable endothelial cells that upon expansion maintain their angiogenic profile without differentiating into nonendothelial cell types. Here, we show that differentiation of hESCs into a large number of stable and proliferative endothelial cells can be achieved by early-stage TGFb-mediated mesoderm induction followed by TGFb inhibition beginning at day 7 (phase 1) and after isolation at day 14 (phase 2). Using this approach, we achieved a 36-fold net expansion of committed endothelial cells. The increased yield allowed transcriptional analysis, which revealed a molecular signature that sheds light on the regulatory influences that govern embryonic vasculogenesis. Indeed, genes encoding a stable BAC transgenic hESC line 20 containing yellow fluorescent protein driven by the Id1 promoter (Id1-YFP) (Fig. 3b-f) (Nam, H.S. and Benezra, R., unpublished data). Differentiated endothelial cells were isolated at day 14 from Id1-YFP cultures (Fig. 1d) , sub-fractionating the CD31 + population into Id1-YFP high-expressing (Fig. 3c) and low-expressing (Fig. 3d) cells, and these populations were serially expanded for 7 d with or without the TGFb inhibitor (Fig. 3e,f) . Flow cytometric analysis of these cells revealed a direct relationship between upregulation of Id1 expression and TGFb inhibition. Notably, although SB431542 increased the percentage of the CD31 + population, the mean fluorescence intensity of CD31 on these cells was lower than that of unstimulated cells. These data suggested that TGFb inhibition increased expansion of hESC-derived endothelial cells by maintaining high levels of Id1 expression and preserving an immature proliferative phenotype.
To determine the requirement for Id1 in mediating endothelial cell commitment, we transduced hVPr-GFP + cells with lentiviral short hairpin (sh)RNA targeted against the Id1 transcript (Fig. 4a,b) . In the presence of SB431542, knockdown of Id1 reduced the numbers of both VEGFR2 + vascular progenitors and hVPr-GFP + cells at day 14. When the Id1 shRNA construct was introduced after isolation of the hVPr-GFP + fraction (Fig. 4c) , it elicited a marked decrease in CD31 + endothelial cells after 5 d of SB431542 treatment (Fig. 4d) . These results identified TGFb inhibitionmediated Id1 upregulation as a primary effector in promoting endothelial cell expansion and maintaining long-term vascular identity. l e T T e R S factors associated with vascular progenitor identity (Id1 high , VEGFR2 high , CD133) [12] [13] [14] [15] [16] [17] 19 as well as vascular markers (PECAM, VE-cadherin, ephrinB2) were highly expressed in hESC-derived endothelial cells and, among these factors, Id1 was found to act downstream of TGFb inhibition to increase endothelial cell yield by promoting proliferation and preserving vascular commitment. These studies establish TGFb modulation of Id1 expression as a determinant of hESC-derived endothelial cell identity and set the stage for large-scale generation of authentic long-lasting human endothelial cells for therapeutic vascularization. Our use of vascular-specific hVPr-GFP and Id1-YFP hESC reporter lines in small-molecule screens allowed the discovery of the TGFb inhibitor SB431542 as a key stimulus for human endothelial cell differentiation and proliferation in serum-free conditions. In murine ESCs, TGFb and serum factors promote smooth muscle cell differentiation, whereas inhibition of this pathway promotes formation of CD31 + cells 21 . Our data show that stage-specific TGFb inhibition, beginning on day 7 at a point following TGFb-mediated mesoderm induction, increases the mitotic index and maintenance of hESC-derived endothelial cells by upregulation of Id1 expression. Differentiation of hVPr-GFP hESCs with TGFb inhibition generated endothelial cells at yields tenfold greater than those of cells differentiated with angiogenic factors alone, and after purification, TGFb inhibition supported endothelial cell expansion for up to ten cell divisions while retaining the angiogenic surface phenotype. The ability of TGFb inhibition to increase endothelial cell yield in both differentiating (phase 1) and purified (phase 2) cultures resulted in a 36-fold increase in the absolute number of hESC-derived endothelial cells, with 95% of the population maintaining endothelial cell identity. As such, we have established a means of generating a homogenous population of stable endothelial cells in ratios that greatly exceed hESC input and are relevant to therapeutic vasculoplasty.
Expression of Id1 has been shown to inhibit cell differentiation and growth arrest in multiple cell types 22 . The TGFb signaling pathway, through the effectors Smad3 and ATF3, has been shown to repress Id1 promoter activity 23 . The link between TGFb signaling, Id1 and preservation of proliferation and phenotypic identity of hESC-derived endothelial cells provides insight into the molecular mechanisms that regulate vascular ontogeny during human development. Indeed, these results point toward a biphasic role for TGFb signaling during vasculogenesis, whereby early activation of this pathway is required for specification of mesodermal progenitors, and inhibition after vascular commitment functions to increase mitotic index and prevent the loss of endothelial identity. Our approach for vascular monitoring and differentiation may enable the identification of as-yet unrecognized vasculogenic and angiogenic modulators for preclinical studies aimed at the cell-based therapeutic revascularization of ischemic tissues.
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